Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that the late-breaking abstracts accepted for presentation at the Endocrine Society's annual meeting (ENDO 2024) were released earlier than the previously announced embargoed date.
The abstract for the Phase 2, open-label study of atumelnant* (CRN04894), in Congenital Adrenal Hyperplasia contained summary data for four subjects at the time of submission. We plan to present additional data from a total of six subjects in cohort 1 and additional subjects in cohort 2 at ENDO 2024.
The more fulsome data set will be shared within the poster presentations scheduled to be presented on June 3, 2024, at 12:00 – 1:30 pm ET during the Late-Breaking Poster Presentation session.
*Proposed international nonproprietary name under review